- Open Access
MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression
- Marilyne Kpetemey†1, 2,
- Subhamoy Dasgupta†1, 2,
- Smrithi Rajendiran1, 2,
- Susobhan Das1, 2,
- Lee D. Gibbs1, 2,
- Praveenkumar Shetty1, 2,
- Zygmunt Gryczynski1, 2 and
- Jamboor K. Vishwanatha1, 2, 3Email author
© Kpetemey et al. 2015
- Received: 10 April 2015
- Accepted: 5 August 2015
- Published: 15 August 2015
Migration and invasion enhancer 1 (MIEN1) is a novel gene found to be abundantly expressed in breast tumor tissues and functions as a critical regulator of tumor cell migration and invasion to promote systemic metastases. Previous studies have identified post-translational modifications by isoprenylation at the C-terminal tail of MIEN1 to favor its translocation to the inner leaflet of plasma membrane and its function as a membrane-bound adapter molecule. However, the exact molecular events at the membrane interface activating the MIEN1-driven tumor cell motility are vaguely understood.
MIEN1 was first studied using in-silico analysis on available RNA sequencing data of human breast tissues and its expression was ascertained in breast cells. We performed several assays including co-immunoprecipitation, wound healing, western blotting and immunofluorescence to decipher the molecular events involved in MIEN1-mediated tumor cell migration.
Clinically, MIEN1 is predominantly overexpressed in Her-2 and luminal B subtypes of breast tumors, and its increased expression correlates with poor disease free survival. Molecular studies identified a phosphorylation-dependent activation signal in the immunoreceptor tyrosine based activation motif (ITAM) of MIEN1 and the phosphorylation-deficient MIEN1-mutants (Y39F/50 F) to regulate filopodia generation, migration and invasion. We found that ITAM-phosphorylation of MIEN1 is significantly impaired in isoprenylation-deficient MIEN1 mutants indicating that prenylation of MIEN1 and membrane association is required for cross-phosphorylation of tyrosine residues. Furthermore, we identified MIEN1 as a novel interactor of Annexin A2 (AnxA2), a Ca2+ -dependent phospholipid binding protein, which serves as an extracellular proteolytic center regulating plasmin generation. Fluorescence resonance energy transfer (FRET) confirmed that MIEN1 physically interacts with AnxA2 and functional studies revealed that they mutually cooperate to accentuate tumor cell motility. Interestingly, our study identified that ectopic overexpression of MIEN1 significantly enhances Tyr23-phosphorylation on AnxA2, thereby stimulating cell surface translocation of AnxA2 and catalyzing the activation of its proteolytic activity.
Our data show that the presence and interaction of both MIEN1 and AnxA2 in breast tumors are crucial drivers of cell motility. Our study has now deciphered a novel regulatory network governing the vicious process of breast tumor cell invasion-metastasis, and findings suggest MIEN1-AnxA2 as prospective targets to counter the deadly disease.
- Annexin A2
- Breast cancer
Migration and invasion enhancer 1(MIEN1) (also known as C35, C17orf37, RDX12, and MGC14832) is located in the chromosomal region 17q12-21, in the ERBB2 amplicon [1–4]. MIEN1 is frequently amplified along the neighboring genes, ErBB2 and GRB7 in variety of tumors including breast cancer. Our previous studies identified MIEN1 as the prime regulator of cancer cell migration and invasion . In addition, we demonstrated that MIEN1 has a functional isoprenylation ‘CAAX’ motif at the C-terminal tail that is post-translationally modified by geranyl-geranyl transferase-I (GGTase-I) . Prenylated MIEN1 then translocates to the inner leaflet of the plasma membrane and potentiates filopodia formation whereas prenylation-deficient MIEN1-mutants fail to migrate, invade and display reduced metastatic capacity in cancer mouse models. However, the exact molecular events at the membrane interface in MIEN1-driven breast tumor cell motility are poorly understood.
The onset of metastasis depends primarily on the ability of tumor cells to detach from basement membranes by cleaving extracellular matrix proteins and promoting motility and invasion to propel forward [7–11]. One of the key factors regulating the extracellular proteolytic process is the plasmin-plasminogen system; which is composed of a proteolytic cascade comprising the two plasminogen activators- tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) [12–18]. Activation of this proteolytic cascade converts the inactive trypsin-like endopeptidases into potent plasmin, which then cleaves the components of the extracellular matrix proteins thereby facilitating rapid migration and invasion of tumor cells to distant organs.
Here, we report that MIEN1 regulates breast cancer cell migration and invasion in a bifunctional mechanism. We show that MIEN1 has a functional immunoreceptor tyrosine based activation motif (ITAM) cross-phosphorylated at two tyrosine-residues (Y39 and Y50), which is important for triggering downstream signal transduction. In addition, we discovered MIEN1 as a novel interacting partner of Annexin A2, a member of the Annexin family of Ca2+-dependent phospholipid binding proteins [19, 20]. Functional studies confirmed interaction of MIEN1 with AnxA2 at the membrane interface is necessary for activation of plasmin-plasminogen complex, thereby facilitating breast cancer cell migration and invasion. Our study identified a novel regulatory pathway for activating extracellular plasmin generation to promote enhanced breast cancer cell migration and invasion.
MIEN1 is expressed in all subtypes of breast cancer
MIEN1 has a functional ITAM-motif
Since, MIEN1 is also modified by isoprenylation at the C-terminal ‘CVIL’ end responsible for its membrane localization , we investigated whether phosphorylation of ITAM-tyrosine residues is dependent on isoprenylation. For this, we analyzed the tyrosine-phosphorylation status of MIEN1 in NIH3T3 cells (with low endogenous MIEN1) transfected with GFP vector only, MIEN1WT or prenylation-deficient MIEN1C112S constructs. In addition, the MIEN1WT expressing cells were either treated with a pharmacological inhibitor against GGTase enzyme GGTI (geranylgeranyl transferase I inhibitor) or vehicle control (DMSO). MIEN1WT expressing cells showed robust tyrosine-phosphorylation whereas GGTI treatment severely abrogated the effect similar to the MIEN1C112S expressing cells (Fig. 2c). These data indicate that tyrosine-phosphorylation of MIEN1 in the ITAM-domain is dependent on prior isoprenylation. These results demonstrate that correct localization of the protein to the plasma membrane is required for subsequent post-translational modification via tyrosine-phosphorylation at the ITAM-domain.
Relative importance of ITAM and CAAX motifs in MIEN1- induced migration
Cell migration is the result of coordination between membrane protrusive structures at a leading edge, adhesion and de-adhesion followed by translocation of the cell body in the direction of migration. In migrating cells, protrusive structures such as filopodia are the pioneers, which probe the environment for cues and guide cell migration. MIEN1 has been shown to induce filopodia formation and mutation of the isoprenyl motif impaired this function . Here we inquired whether the ITAM regulates MIEN1-induced filopodia, aside from the isoprenyl motif. NIH3T3 cells expressing various constructs of MIEN1 were stained with rhodamine-conjugated phalloidin and subjected to immunofluorescence analysis post wound induction. Stable expression of MIEN1 in NIH3T3 cells visibly increased the number and length of filopodia post wound induction compared to MIEN1-mutants expressing cells (Fig. 3i–n) confirming that ITAM and CAAX are important for MIEN1 function. Immunoblotting analysis of cells expressing vector control and MIEN1 constructs confirmed the equal expression of the wild type and mutants MIEN1 protein (Fig. 3o).
MIEN1 is an interactor of AnxA2
MIEN1 enhances AnxA2 phosphorylation to promote cell surface translocation and breast cancer cell migration
MIEN1 activates AnxA2 dependent extracellular proteolytic functions
Cell motility process is a highly coordinated event integrated by extensive transient signaling networks of proteins [31, 32]. Protein–protein interactions are the underlying backbone of migratory processes including actin structures, proteolytic enzymes that degrade the ECM and the coordination between detachment/re-adhesion cycles . Here we report the dynamics of MIEN1-induced signaling that regulate tumor cell migration and invasion.
MIEN1 expression is significantly increased in breast cancer cells and analysis of TCGA database showed that elevated expression of MIEN1 correlates with poor survival of breast cancer patients. Several post-translational modifications regulate MIEN1 protein functions and downstream signaling events. In addition to isoprenylation, in this study we identified that phosphorylation of tyrosine residues (Y39 and Y50) in the ITAM motif is important for its function. Signal transduction by ITAM is initiated by the phosphorylation of the tyrosine residues within the ITAM sequence, followed by the recruitment of members of the Syk kinase family [34–36]. The binding of Syk to the phosphorylated-ITAM results in the activation of multiple signaling cascades. Previous studies indicated that Syk kinase potentiates MIEN1 dependent signaling in breast tumor cells . Using phospho-deficient single or double mutants, we show that MIEN1 is tyrosine phosphorylated in the ITAM motif. In addition, we also demonstrate that isoprenylation and membrane localization is important for ITAM-phosphorylation. Blocking isoprenylation of MIEN1 using GGTase inhibitors or genetic mutation of the ‘CVIL’ prenylation domain significantly impairs ITAM-or tyrosine phosphorylation. These findings indicate that ITAM-dependent signal transduction by MIEN1 depends on prior isoprenylation and correct localization of the protein to the inner leaflet of plasma membrane. As expected, ITAM phosphorylation was also important for MIEN1-dependent migration and invasion as phospho-deficient MIEN1 mutants severely impaired breast cancer cell migration and invasion.
Interestingly, we identified MIEN1 as an important interactor of AnxA2. A multifunctional protein, AnxA2 is involved in various cellular activities and its dysregulation is implicated in multiple diseases including breast cancer . Although, AnxA2 is predominantly a cytosolic protein, phosphorylation on its N-terminal Y23 translocates the protein to the cell surface [38, 39]. Cell surface AnxA2 interacts with plasminogen and tPA and mediates the conversion of plasminogen to plasmin . In breast cancer, AnxA2 mediated plasmin activation is shown to be essential for angiogenesis, migration and invasion which are critical events in disease metastasis.
Our data provide evidence that MIEN1 interaction with AnxA2 enhances Y23 phosphorylation of AnxA2 and subsequent translocation of the protein to the cell surface leads to increased plasmin levels which support breast tumor cell motility. Although, MIEN1 does not have a kinase domain, we believe this phosphorylation on AnxA2 is a downstream signaling event regulated by MIEN1.
Our studies convincingly demonstrate that interaction of MIEN1 with AnxA2 is required for extracellular plasmin generation thereby increasing breast cancer cell migration and invasion. Our findings place MIEN1 and anxA2 as attractive therapeutic targets for blocking invasive cancers.
In silico analysis
MIEN1 was first studied using in-silico analysis on available DNA microarray and RNA sequencing data of breast tumors and normal tissues from TCGA website (http://cancergenome.nih.gov/) and the bc-GenExMiner database v3.1 (http://bcgenex.centregauducheau.fr/BC-GEM/GEM_Accueil.php?js=1). The breast cancer gene-expression Miner v3.1 was utilized to assess MIEN1 expression in breast cancer molecular subtypes. Bc-GenEXMiner analyzes available gene expression data sets from repositories such as Gene Expression Omnibus (GEO), Array Express and Stanford microarray database [41–43]. The analysis was performed through a built-in robust single sample predictor (SSP) classification (RSSPC), which includes intersection of three SSPs . The UCSC Cancer Genomics Browser can be accessed through https://genome-cancer.ucsc.edu/ and following the central hyperlink. The UCSC Cancer Genomics Browser displays the genomic, clinical and annotation data in multiple views [45–50]. We used the breast cancer gene expression (BRCA) (IlluminaHiSeq) dataset followed by subgrouping for C17orf37 (MIEN1) expression. Subgroups allow users to group samples according to an arbitrary combination of annotation data values. We stratified the BRCA dataset according to MIEN1 expression: low (green from 0.0 to −6.67) and high (red from 1.0 to 6.34) followed by Kaplan Meier plot to generate the survival percentage over time (days) with respect to MIEN1 expression.
GFP-MIEN1 (MIEN1WT) was generated by PCR amplification of full-length human MIEN1 cDNA (347 base pairs) and directionally cloned into pEGFP-C1 vector as previously described [5, 6]. GFP-MIEN1 mutants were generated using QuikChange multi-site-directed mutagenesis kit from Stratagene (La Jolla, CA, USA) from the GFP-MIEN1WT template.
MIEN1 and AnxA2 small interfering RNA transfection in breast cancer cells
Human MIEN1 smart pool siRNA and AnxA2 smart pool siRNA were used for knock-down experiments (Dharmacon, Lafayette, CO). Green fluorescent protein (GFP) siRNA (Qiagen, Germatown, MD) served as control. Breast cancer cells were transfected with siRNA duplex at a concentration of 40 nM using Lipofectamine RNAiMAX purchased from Invitrogen (Grand Island, NY, USA).
Cell lines and culture conditions
NIH3T3 mouse fibroblast cells and human breast cancer cell lines (SKBR-3, BT-474, MDA-MB231, MDA-MB4-36, HCC-70, HCC-1937, MCF-7, T47D) were obtained from American type culture collection. MCF10A, MCF10AT, MCF10CA1a, MCF10CA1d, MCF10CA1h cells were obtained from Karmanos cancer center, and JIMT-1 from Leibniz-Institut DSMZ. All cell lines were maintained in a humidified incubator containing 5 % CO2/95 % air at 37 °C. Stable NIH3T3 and MDA-MB231 cells expressing GFP-MIEN1 constructs were generated using 500 μg/ml and 650 μg/ml G418 antibiotic (Invitrogen).
Yeast two-hybrid screening
A yeast two-hybrid screening was carried out as described previously. Full-length human AnxA2 cDNA (GenBank entry NM_004039) fragment was cloned into pGBKT7 vector (Clontech). The recombinant plasmid used was GAL4 DNA binding bait (DNA-BD/bait) and transformed into AH109 yeast cells screened for growth on synthetic dropout (SD/-Trp) medium. A human placental pre-transformed cDNA library (Clontech) was used for screening interacting proteins. This library was made using the recombinant vector pGADT7, which contains the activation domain (DNA-Ac/library) with a different nutrient marker -Leu and was transformed into strain Y187 and screened for growth on SD/-Leu medium. The interaction screening was conducted by mating the DNA-BD/ bait strain and DNA-Ac/library strain, and the positive clones were selected. Positive clones were selected on high-stringency medium with selection markers SD/-Ade/-His/-Leu/-Trp/ X-R-gal and then screened as described above (Clontech). Positive yeast clones were selected by prototrophy for histidine or expression of β-galactosidase and then subjected to sequence analysis to search for novel interacting proteins.
FLIM based forster resonance energy transfer (FRET) assay
FRET was performed as described previously with minor modifications . Briefly, cells were immunostained for MIEN1 and AnxA2, labeled with donor Alexa-488 and acceptor fluorophore Alexa-594, respectively. Upon transfer of energy from the donor to the acceptor, the donor fluorophore’s lifetime was monitored as an indicator for the presence or absence of FRET.
Determination of the förster distance (R0)
Immnunoprecipitation and immunoblotting assays
Immunoprecipitation and immunoblotting were performed as described previously . In brief cells were lysed with NP-40 lysis buffer supplemented with protease and phosphatase inhibitor cocktail (Millipore, Billerica, MA). The supernatants were taken as the total cell lysates; and using protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA), AnxA2 and MIEN1 were immunoprecipitated. The immunoprecipitated proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes for immunoblotting. The antibodies used were MIEN1 from Abnova (Taipei, Taiwan), AnxA2 (Santa Cruz Biotechnology) and β-actin (Santa Cruz Biotechnology)
Migration and invasion assay
Cells were grown in a monolayer and upon reaching confluence, the cell layer was scratched using a sterile micropipette tip. The wound was imaged at the indicated time points following wound creation. Representative images were captured and analyzed using Image J software. Invasion assays were performed using HTS FluoroBlok multi well insert system from BD Falcon, (San Jose, CA, USA) as previously described .
Cells were fixed using 4 % paraformaldehyde (Affymetrix, Santa Clara, CA, USA) and stained with rhodamine-conjugated phalloidin, MIEN1 and AnxA2 primary antibodies followed by Alexa Fluor 488 and 594 secondary antibodies (Invitrogen). Cells were mounted on glass coverslips with Prolong Gold mounting medium (Invitrogen). Confocal images were acquired using Zeiss confocal microscope LSM510.
Total internal reflection fluorescence (TIRF) microscopy
For TIRF microscopy, MDA-MB231 cells were grown on coverslips and then transfected with empty vector or GFP-MIEN1 wild type. The cells were fixed with 4 % paraformaldehyde, permeabilized with 0.1 % Triton X-100, washed with PBS and blocked with BSA. Cells were subsequently treated with AnxA2 (BD Biosciences) and phospho-AnxA2 Tyr23 (Santa Cruz Biotechnology) antibodies followed by AlexaFlour 488 conjugated secondary antibody and mounted with Permafluor mounting medium. For TIRF images, the cells were visualized on an Olympus IX71 microscope with commercial TIRF attachment as described previously by 60 × oil immersion objective .
Plasminogen activation assays
The assay was performed according to the previously established protocols . In brief, HCC-70 and MCF-7 cells were transfected with GFP, MIEN1 and/or AnxA2 siRNA. Cells were then incubated with recombinant 10 nM human tPA and 100 nM Glu-plasminogen and subsequently treated with the fluorogenic plasmin substrate, D-VLK-AMC (D-Val-Leu-Lys-7-amido-4-methylcoumarin; Sigma). Substrate hydrolysis was measured for 12 h. Results were obtained as fluorescence units (FUs) using a fluorescence spectrophotometer (380 nm excitation and 460 nm emission wavelengths).
Data acquired from migration, invasion, immunofluorescence and plasmin generation assays were analyzed using student t-test. The statistical analysis was performed using Windows version of SPSS along with GraphPad Prism 4.02 software. The ImageJ software was used for wound healing assay analysis. Significance was defined as *P < 0.05, **P < 0.01, ***P < 0.001 compared to controls and between different treatment groups.
We would like to thank the microscopy core facility at the Center for Commercialization of Fluorescent Technologies at University of North Texas Health Science Center for their help. We also extend our gratitude to Dr. Irina Akapova for her help on the FRET studies.
This work was supported in part by National Institute on Minority Health and Health disparities Grant 1P20 MD006882 to JKV.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol. 2003;163:1979–84.PubMed CentralView ArticlePubMedGoogle Scholar
- Evans EE, Henn AD, Jonason A, Paris MJ, Schiffhauer LM, Borrello MA, et al. C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Mol Cancer Ther. 2006;5:2919–30.View ArticlePubMedGoogle Scholar
- Deblois G, Chahrour G, Perry MC, Sylvain-Drolet G, Muller WJ, Giguere V. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Cancer Res. 2010;70:10277–87.View ArticlePubMedGoogle Scholar
- Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A, et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010;12:R25.PubMed CentralView ArticlePubMedGoogle Scholar
- Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, Vishwanatha JK. Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene. 2009;28:2860–72.PubMed CentralView ArticlePubMedGoogle Scholar
- Dasgupta S, Cushman I, Kpetemey M, Casey PJ, Vishwanatha JK. Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. J Biol Chem. 2011;286:25935–46.PubMed CentralView ArticlePubMedGoogle Scholar
- Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol. 2008;3:221–47.View ArticlePubMedGoogle Scholar
- Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett. 2009;284:122–30.View ArticlePubMedGoogle Scholar
- Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol. 2009;185:11–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Palmer TD, Ashby WJ, Lewis JD, Zijlstra A. Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev. 2011;63:568–81.PubMed CentralView ArticlePubMedGoogle Scholar
- Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 2013;34:283–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhou HM, Nichols A, Meda P, Vassalli JD. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J. 2000;19:4817–26.PubMed CentralView ArticlePubMedGoogle Scholar
- Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25–40.View ArticlePubMedGoogle Scholar
- Andronicos NM, Ranson M. The topology of plasminogen binding and activation on the surface of human breast cancer cells. Br J Cancer. 2001;85:909–16.PubMed CentralView ArticlePubMedGoogle Scholar
- Ranson M, Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003;8:s294–304.View ArticlePubMedGoogle Scholar
- Palumbo JS, Talmage KE, Liu H, La Jeunesse CM, Witte DP, Degen JL. Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. Blood. 2003;102:2819–27.View ArticlePubMedGoogle Scholar
- Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol. 2012;2012:564259.PubMed CentralView ArticlePubMedGoogle Scholar
- Paoletti C, Hayes DF. Molecular testing in breast cancer. Annu Rev Med. 2014;65:95–110.View ArticlePubMedGoogle Scholar
- Grewal T, Enrich C. Annexins — Modulators of EGF receptor signalling and trafficking. Cell Signal. 2009;21:847–58.View ArticlePubMedGoogle Scholar
- Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 2013;14:6259–305.PubMed CentralView ArticlePubMedGoogle Scholar
- Katz E, Dubois-Marshall S, Sims AH, Faratian D, Li J, Smith ES, et al. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer. 2010;103:401–10.PubMed CentralView ArticlePubMedGoogle Scholar
- Wong YH, Lee TY, Liang HK, Huang CM, Wang TY, Yang YH, et al. KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. Nucleic Acids Res. 2007;35:W588–594.PubMed CentralView ArticlePubMedGoogle Scholar
- Shen HB, Chou KC. QuatIdent: a web server for identifying protein quaternary structural attribute by fusing functional domain and sequential evolution information. J Proteome Res. 2009;8:1577–84.View ArticlePubMedGoogle Scholar
- Safaei J, Manuch J, Gupta A, Stacho L, Pelech S. Prediction of 492 human protein kinase substrate specificities. Proteome Sci. 2011;9 Suppl 1:S6.PubMed CentralView ArticlePubMedGoogle Scholar
- Dinkel H, Van Roey K, Michael S, Davey NE, Weatheritt RJ, Born D, et al. The eukaryotic linear motif resource ELM: 10 years and counting. Nucleic Acids Res. 2014;42:D259–266.PubMed CentralView ArticlePubMedGoogle Scholar
- Valapala M, Thamake SI, Vishwanatha JK. A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J Cell Sci. 2011;124:1453–64.PubMed CentralView ArticlePubMedGoogle Scholar
- Valapala M, Maji S, Borejdo J, Vishwanatha JK. Cell surface translocation of annexin A2 facilitates glutamate-induced extracellular proteolysis. J Biol Chem. 2014;289:15915–26.PubMed CentralView ArticlePubMedGoogle Scholar
- Flood EC, Hajjar KA. The annexin A2 system and vascular homeostasis. Vasc Pharmacol. 2011;54:59–67.View ArticleGoogle Scholar
- Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, et al. Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci. 2011;31:14346–60.PubMed CentralView ArticlePubMedGoogle Scholar
- Sharma M, Ownbey RT, Sharma MC. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol. 2010;88:278–86.View ArticlePubMedGoogle Scholar
- Stupack DG, Cho SY, Klemke RL. Molecular signaling mechanisms of cell migration and invasion. Immunol Res. 2000;21:83–8.View ArticlePubMedGoogle Scholar
- Vicente-Manzanares M, Horwitz AR. Cell migration: an overview. Methods Mol Biol. 2011;769:1–24.View ArticlePubMedGoogle Scholar
- Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003;112:453–65.View ArticlePubMedGoogle Scholar
- Underhill DM, Goodridge HS. The many faces of ITAMs. Trends Immunol. 2007;28:66–73.View ArticlePubMedGoogle Scholar
- Hirose M, Kitano J, Nakajima Y, Moriyoshi K, Yanagi S, Yamamura H, et al. Phosphorylation and recruitment of Syk by immunoreceptor tyrosine-based activation motif-based phosphorylation of tamalin. J Biol Chem. 2004;279:32308–15.View ArticlePubMedGoogle Scholar
- Fueller F, Kubatzky KF. The small GTPase RhoH is an atypical regulator of haematopoietic cells. Cell Commun Signal. 2008;6:6.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang F, Liu Y, Wang Z, Sun X, Yuan J, Wang T, et al. A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level. Mol Cell Endocrinol. 2015;411:75–85.View ArticlePubMedGoogle Scholar
- Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem. 2004;279:43411–8.View ArticlePubMedGoogle Scholar
- Valapala M, Vishwanatha JK. Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem. 2011;286:30911–25.PubMed CentralView ArticlePubMedGoogle Scholar
- Dutta S, Bandyopadhyay C, Bottero V, Veettil MV, Wilson L, Pins MR, et al. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration. Mol Oncol. 2014;8:483–507.View ArticlePubMedGoogle Scholar
- Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G, et al. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 2012;131:765–75.View ArticlePubMedGoogle Scholar
- Jezequel P, Frenel JS, Campion L, Guerin-Charbonnel C, Gouraud W, Ricolleau G, et al. bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database (Oxford). 2013;2013:bas060.View ArticleGoogle Scholar
- Jezequel P, Juin PP, Campone M. [<< Bioinfomics >>: a new research field]. Bull Cancer. 2014;101:118–9.PubMedGoogle Scholar
- Weigelt B, Mackay A, A’Hern R, Natrajan R, Tan DS, Dowsett M, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010;11:339–49.View ArticlePubMedGoogle Scholar
- Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, et al. The UCSC Cancer Genomics Browser. Nat Methods. 2009;6:239–40.View ArticlePubMedGoogle Scholar
- Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010;26:i237–245.PubMed CentralView ArticlePubMedGoogle Scholar
- Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, et al. The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Res. 2011;39:D951–959.PubMed CentralView ArticlePubMedGoogle Scholar
- Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep. 2013;3:2652.PubMed CentralView ArticlePubMedGoogle Scholar
- Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, et al. The UCSC Cancer Genomics Browser: update 2013. Nucleic Acids Res. 2013;41:D949–954.PubMed CentralView ArticlePubMedGoogle Scholar
- Goldman M, Craft B, Swatloski T, Cline M, Morozova O, Diekhans M, et al. The UCSC Cancer Genomics Browser: update 2015. Nucleic Acids Res. 2015;43:D812–817.PubMed CentralView ArticlePubMedGoogle Scholar
- Das S, Shetty P, Valapala M, Dasgupta S, Gryczynski Z, Vishwanatha JK. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells. Biochemistry. 2010;49:2216–26.View ArticlePubMedGoogle Scholar